1-3 of 3
Dorte Gillstrøm
Close
Sort by
Journal Articles

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Francesco d'Amore, Judit Joergensen, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Bjarne Bach Pedersen, Dorte Gillström, Michael Clausen, Peter Kamper, Trine Silkjaer, Lars C. Gormsen, Sirpa Leppä, Helle Toldbod
Journal: Blood
Blood (2014) 124 (21): 5435.
https://doi.org/10.1182/blood.V124.21.5435.5435
Published: 2014
Journal Articles

Prognostic Impact of Clinician-Based Interpretation of FDG-PET/CT Reports Obtained in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Karen Juul Mylam, Tarec Christoffer El-Galaly, Peter de Nully Brown, Bodil Himmelstrup, Dorte Gillstrøm, Ida Blok Sillesen, Lars Munksgaard, Bjarne Bach Pedersen, Ilse Christiansen, Paw Jensen, Anne Lerberg Nielsen, Lars Møller Pedersen
Journal: Blood
Blood (2012) 120 (21): 2646.
https://doi.org/10.1182/blood.V120.21.2646.2646
Published: 2012
Journal Articles

90 y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Arne Kolstad, Anna Laurell, Niels S Andersen, Erkki Elonen, Riikka Raty, Lone Bredo Pedersen, Annika Loft, Trond Velde Bogsrud, Marie Nordstrom, Dorte Gillstrom, Per Boye Hansen, Hans Bentzen, Unn-Merete Fagerli, Peter Meyer, Herman Nilsson-Ehle, Mats Jerkeman, Anne Kristine Lehmann, Grete F Lauritzsen, Christer Sundstrom, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Elisabeth Ralfkiaer, Mats Ehinger, Christian H. Geisler
Journal: Blood
Blood (2009) 114 (22): 932.
https://doi.org/10.1182/blood.V114.22.932.932
Published: 2009